Autopsy report · NCT05712694
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Cause of deathFutility
“Lack of Efficacy, no safety concern.”
Life of this trial
- Registered 1 year before it started.
- Ran for about 2 years 6 months before it stopped.
- 218 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Polaris Group
- Sponsor type
- Industry
- Conditions
- Soft Tissue Sarcoma
- Interventions
- ADI PEG20; Placebo
- Participants
- 218
- Sites
- 30
- Countries
- Canada, Taiwan, United States
Trials that died the same way
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
“Not related to safety concerns or lack of efficacy” - Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
“Lack of efficacy of the drug; no safety concern” - MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
“Business Decision; No Safety Or Efficacy Concerns.” - A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
“Business decision, insufficient enrollment, no safety or efficacy concerns.” - Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
“Due to a lack of safety and efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.